SCHEMBL1060971

SCHEMBL1060971

COC(=O)c1ccc(CSc2nc3ccc(N)cc3s2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.67
MAPT P10636 9/20 0.65
ALDH1A1 P00352 6/20 0.65
KMT2A Q03164 5/20 0.65
MEN1 O00255 4/20 0.65
LMNA P02545 2/20 0.65
NPC1 O15118 5/20 0.60
RAB9A P51151 5/20 0.60
HPGD P15428 1/20 0.56
SHMT2 P34897 1/20 0.56
TP53 P04637 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
KDM4E B2RXH2 1/20 0.55
HTT P42858 1/20 0.55
GFER P55789 1/20 0.54
CYP3A4 P08684 2/20 0.53
CYP2C9 P11712 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14439016 0.88 CYP1A2 (0.62) CYP1A2MAPTALDH1A1KMT2ALMNA
SCHEMBL2733017 0.84 CYP1A2 (0.58) CYP1A2MAPTALDH1A1LMNANPC1
SCHEMBL209386 0.80 MAPT (0.62) CYP1A2MAPTLMNATP53SMN1; SMN2
SCHEMBL210098 0.80 CYP1A2 (0.53) CYP1A2MAPTALDH1A1KMT2ALMNA
SCHEMBL210097 0.80 CYP1A2 (0.53) CYP1A2MAPTALDH1A1KMT2ALMNA
SCHEMBL2732646 0.80 CYP1A2 (0.53) CYP1A2MAPTALDH1A1KMT2ALMNA
SCHEMBL8991265 0.78 MAPT (0.74) CYP1A2MAPTALDH1A1KMT2AMEN1
SCHEMBL1065942 0.77 HDAC1 (0.70) CYP1A2MAPTLMNATP53POLB
SCHEMBL10756678 0.77 MAPT (0.78) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL6635501 0.75 MAPT (0.67) MAPTALDH1A1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 US disclosed
US-7868204-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-7838520-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2010-11-23 US disclosed
US-7595343-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2009-09-29 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 US disclosed
US-20060058298-A1 Inhibitors of histone deacetylase METHYLGENE, INC. 2006-03-16 US disclosed
US-20050288282-A1 Inhibitors of histone deacetylase METHYLGENE, INC. 2005-12-29 US disclosed
EP-1590340-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2005-11-02 EP disclosed
WO-2005092899-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2005-10-06 WO disclosed
US-6897220-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2005-05-24 US disclosed
WO-2004069823-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2004-08-19 WO disclosed
US-20040142953-A1 Inhibitors of histone deacetylase METHYLGENE, INC. 2004-07-22 US disclosed
EP-1429765-A2 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2004-06-23 EP disclosed
US-20040106599-A1 Inhibitors of histone deacetylase 92229129 QUEBEC INC. (CA) 2004-06-03 US disclosed
WO-2003024448-A2 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288282-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 CYP1A2 4430/4885MAPT 2110/4885ALDH1A1 796/4885
US-20040106599-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 CYP1A2 4430/4885MAPT 2110/4885ALDH1A1 796/4885
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 CYP1A2 4230/4885MAPT 3612/4885ALDH1A1 680/4885
US-20060058298-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 CYP1A2 4430/4885MAPT 2110/4885ALDH1A1 796/4885
US-20040142953-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 CYP1A2 4430/4885MAPT 2110/4885ALDH1A1 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.